Cantor Fitzgerald Comments on AVITA Medical FY2026 Earnings

AVITA Medical, Inc. (NASDAQ:RCEL) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for AVITA Medical in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings of ($0.23) per share for the year. The consensus estimate for AVITA Medical’s current full-year earnings is ($0.95) per share.

Separately, D. Boral Capital reiterated a “buy” rating and set a $19.00 target price on shares of AVITA Medical in a report on Friday, June 6th.

AVITA Medical Trading Up 1.2%

RCEL stock opened at $6.06 on Wednesday. The company has a debt-to-equity ratio of 9.39, a current ratio of 2.83 and a quick ratio of 2.47. AVITA Medical has a 12 month low of $5.46 and a 12 month high of $14.16. The firm’s 50-day moving average is $7.78 and its 200 day moving average is $9.42. The company has a market capitalization of $160.20 million, a PE ratio of -2.54 and a beta of 1.55.

AVITA Medical (NASDAQ:RCEL) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.14). AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%. The firm had revenue of $18.51 million during the quarter, compared to the consensus estimate of $33.15 million.

Institutional Investors Weigh In On AVITA Medical

Several institutional investors and hedge funds have recently made changes to their positions in RCEL. BNP Paribas Financial Markets acquired a new stake in shares of AVITA Medical during the fourth quarter worth $38,000. CWM LLC lifted its stake in shares of AVITA Medical by 1,099.5% during the first quarter. CWM LLC now owns 4,918 shares of the company’s stock worth $40,000 after buying an additional 4,508 shares during the period. GAMMA Investing LLC lifted its stake in shares of AVITA Medical by 688.9% during the first quarter. GAMMA Investing LLC now owns 6,374 shares of the company’s stock worth $52,000 after buying an additional 5,566 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of AVITA Medical during the first quarter worth $53,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of AVITA Medical by 48.0% during the fourth quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company’s stock worth $92,000 after buying an additional 2,324 shares during the period. 27.66% of the stock is currently owned by institutional investors and hedge funds.

About AVITA Medical

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.